Get the Stockscreener App
5.372
6.57%
-0.378
After Hours:
5.80
0.428
+7.97%
Pluri Inc stock is traded at $5.372, with a volume of 48,814.
It is down -6.57% in the last 24 hours and up +40.81% over the past month.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
See More
Previous Close:
$5.75
Open:
$5.7412
24h Volume:
48,814
Relative Volume:
3.00
Market Cap:
$33.24M
Revenue:
$598.00K
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.3039
EPS:
-4.12
Net Cash Flow:
$-16.66M
1W Performance:
+13.09%
1M Performance:
+40.81%
6M Performance:
-2.86%
1Y Performance:
-7.62%
1-Day Range:
$5.11
$5.90
1-Week Range:
$4.7242
$6.10
52-Week Range:
$3.33
$7.13
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Compare PLUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
5.372 | 33.24M | 598.00K | -21.81M | -16.66M | -4.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Pluri Inc Stock (PLUR) Latest News
Pluri Regains Nasdaq Compliance Before Deadline - TipRanks
Renaissance Technologies LLC Boosts Stock Position in Pluri Inc. (NASDAQ:PLUR) - Defense World
Pluri Inc. sets date for 2025 shareholder meeting By Investing.com - Investing.com Canada
Pluri Inc. sets date for 2025 shareholder meeting - Investing.com
Pluri acquires 71% stake in Kokomodo - Food Business News
Pluri Inc. acquires majority stake in Kokomodo Ltd. By Investing.com - Investing.com Canada
Pluri Acquires 71% Of Kokomodo To Advance Climate-Resilient Cultivated Cacao Production - Nasdaq
Pluri Inc. acquires majority stake in Kokomodo Ltd. - Investing.com
$13.5B Cacao Market Disruption: Pluri Acquires Cellular Agriculture Pioneer Kokomodo for Climate-Resilient Future - Stock Titan
Pluri Inc. enters agreement, issues pre-funded warrants - Investing.com Australia
Pluri Inc. enters agreement, issues pre-funded warrants By Investing.com - Investing.com Canada
Pluristem stock soars to 52-week high, hits $6.63 By Investing.com - Investing.com South Africa
Pluristem stock soars to 52-week high, hits $6.63 - Investing.com Australia
DarioHealth Announces CFO Transition - Benzinga
DarioHealth Taps Israeli CFO Excellence Award Winner to Lead Next Growth Phase - Stock Titan
Pluri Inc. subsidiary loses $4.2 million NIAID contract By Investing.com - Investing.com Canada
Pluri Inc. subsidiary loses $4.2 million NIAID contract - Investing.com Australia
Pluri IncPluri Biotech Receives Termination Notice From Niaid Of ContractSEC Filing - marketscreener.com
Analyzing X4 Pharmaceuticals (NASDAQ:XFOR) & Pluri (NASDAQ:PLUR) - Defense World
Pluri Inc. (NASDAQ:PLUR) Short Interest Update - Defense World
Pluri’s immune cell expansion technologies gain patents - Yahoo Finance
Pluri Announces Expansion of Intellectual Property Portfolio wit - GuruFocus
Pluri secures patents for cancer cell therapy expansion tech By Investing.com - Investing.com South Africa
Pluri Inc. Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - MarketScreener
Pluri secures patents for cancer cell therapy expansion tech - Investing.com India
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - TradingView
Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs - Proactive financial news
Pluristem stock touches 52-week low at $4 amid market challenges By Investing.com - Investing.com South Africa
Pluristem stock touches 52-week low at $4 amid market challenges - Investing.com
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-K Report - TradingView
Pluri Inc. (NASDAQ:PLUR) Sees Large Decrease in Short Interest - Defense World
Pluri Inc. sets date for 2025 annual shareholder meeting By Investing.com - Investing.com Canada
Pluri Inc. sets date for 2025 annual shareholder meeting - Investing.com India
Revolutionary Cell Therapy Preservation: Teknova's New PluriFreeze System Transforms Development Process - StockTitan
Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom - openPR
Plurilock Security (CVE:PLUR) Shares Down 5% – Here’s What Happened - Defense World
Using cell science to fight nuclear weapons: How is Pluri revolutionizing health and food tech? - The Jerusalem Post
Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Forecast: Ke... - WhaTech
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):